• All sexes, 18 years and older.

• Participants must speak English, understand, and sign the informed consent document.

• Stated willingness to comply with all study procedures and availability for the duration of the study.

• In good general health as evidenced by medical history and with a clinical diagnosis of inherited retinal dystrophy or dry-AMD.

• Best Corrected Visual Acuity (BCVA) of 20/20 (with constriction or other defects of Goldmann visual field) to Light Perception in the better eye.

• Intact inner nuclear layer, inner plexiform, and ganglion cell layer on macular SD-OCT.

• Ability to take oral medication and be willing to adhere to the disulfiram regimen.

• Patients must have the diagnosis of alcohol use disorder provided by an addiction specialist and be a candidate for therapeutic use of disulfiram for that condition.

• Patients must agree to refrain from all alcohol consumption for 180 days.

• Any female participant of childbearing potential must have a negative urine pregnancy test at screening.

• Any female participant of childbearing potential must have (or have a partner who has) had a surgical sterilization (vasectomy, hysterectomy, or tubal ligation), be completely abstinent from intercourse or must agree to practice two acceptable methods of contraception throughout the course of the study and for at least one week after disulfiram discontinuation. Acceptable methods of contraception include hormonal contraception (i.e., birth control pills, injected hormones, dermal patch, or vaginal ring); intrauterine device; barrier methods (diaphragm, condom) with spermicide.